
Opinion|Videos|July 12, 2024
Evaluating Value of BTK Inhibitors in CLL Treatment
Experts evaluate the value of BTK inhibitors in CLL treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
2
Physical Activity, Vaccination May Protect Against Long COVID
3
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
4
mRNA COVID-19 Vaccines Not Associated With Major Congenital Malformations During Pregnancy
5